Dr. Pradeep Albert
Optimizing Glucose Management for Health and Longevity

Optimizing Glucose Management for Health and Longevity

The Limitations of Standard Blood Glucose Metrics

For decades, hemoglobin A1c (HbA1c) and fasting blood glucose have been the primary metrics used to assess blood sugar control and diagnose conditions like diabetes. However, according to some experts, relying solely on these laboratory blood tests provides an incomplete picture of one’s true glucose metabolism.

HbA1c measures the amount of glucose bound to hemoglobin in red blood cells, giving an estimate of one’s average blood sugar over the previous 3 months. But HbA1c can be misleading – it doesn’t provide insight into short-term blood glucose fluctuations or post-meal “spikes”. And it can be falsely lowered in those with high red blood cell turnover or increased by conditions affecting red blood cell lifespan.

  

Similarly, while fasting glucose is important, it reveals nothing about the body’s ability to stabilize blood sugar in response to carbohydrate intake – a key aspect of metabolic health.

Continuous Glucose Monitoring Allows for More Comprehensive Assessments

Enter continuous glucose monitoring (CGM) – wearable devices that track interstitial fluid glucose levels in real-time. Whereas an HbA1c test or fasting glucose is merely a “snapshot”, CGM provides the full “movie” of one’s metabolic processes in action.

But CGM technology is typically only used in diabetic patients today. Some forward-thinking physicians believe CGM has tremendous untapped potential for assessing and optimizing glucose regulation in non-diabetic, healthy individuals as well.

 

The data provided by CGM facilitates tracking key metrics highly relevant to longevity and disease prevention:

     

  • Average blood glucose – lower averages correlate to better health outcomes
  •  

  • Glucose variability (measured by standard deviation) – the higher the fluctuation in blood sugar, the more damaging
  •  

  • Post-meal glucose spikes – large, prolonged elevations in blood sugar can negatively impact tissues over time
  •   

Metrics and Target Levels

Ideally, one should aim for:

     

  • Average blood glucose under 100 mg/dL (equivalent to an HbA1c under 5.4%)
  •  

  • Standard deviation less than 20 mg/dL, optimally under 15 mg/dL
  •  
     

  • Post-meal peak glucose up to 140 mg/dL, coming back down under 120 mg/dL within 2 hours
  •   

Values significantly higher than these targets over years and decades may accelerate aging pathways and increase risk for many chronic diseases.

Diet, Exercise, Metformin & More

The great part about CGM technology is that it facilitates rapid testing of interventions to improve one’s scores. Want to try a low-carb diet, take up endurance training, start metformin, or experiment with intermittent fasting? The immediate, objective data provided by CGM makes it easy to determine what works best for your body.

This contrasts sharply with the “black box” limitations of infrequent HbA1C tests. CGM enables each person to determine their own optimized lifestyle “prescription” to minimize blood glucose elevations based on their own biology and preferences.

  

The Future of Preventative Medicine?

Wider adoption of continuous glucose monitoring in healthy populations has the potential to radically enhance preventative healthcare and chronic disease outcomes moving forward.

 

Rather than waiting until disease onset before taking action, the early warning signals provided by deteriorations in CGM metrics could trigger earlier interventions. Enabling at-risk patients to preserve metabolic health and avoid ever receiving a diabetes or pre-diabetes diagnosis.

More in Longevity and Anti-Aging

View all →
GLP-1 Gene Therapy: Could Your Body Become Its Own Ozempic Factory?

GLP-1 Gene Therapy: Could Your Body Become Its Own Ozempic Factory?

Biotech companies are closing in on a single-dose gene therapy that programs your own cells to produce GLP-1 — potentially replacing weekly Ozempic injections forever. Here's what the science actually shows.

GLP-1 Gene Therapy – Could Your Body Become Its Own Ozempic Factory?

GLP-1 Gene Therapy – Could Your Body Become Its Own Ozempic Factory?

🎧 View Transcript What if instead of weekly injections of Ozempic or Wegovy, you could receive a single treatment that programs your own cells to produce GLP-1 for the rest of your life? That's the ambitious goal of two biotech startups now racing…

iPSC Therapy Restores Insulin Production: A Regenerative Approach to Type 1 Diabetes

iPSC Therapy Restores Insulin Production: A Regenerative Approach to Type 1 Diabetes

🎧 Audio Overview summary, or read the transcript below: View Audio Transcript A patient with Type 1 diabetes required no insulin injections for over a year following induced pluripotent stem cell therapy. This isn't just remarkable—it demonstrates that regenerative medicine can address the underlying cellular deficit in Type 1 diabetes rather…

GLP-1 Agonists: Beyond Diabetes to a New Era of Metabolic Medicine

GLP-1 Agonists: Beyond Diabetes to a New Era of Metabolic Medicine

🎧 Audio Overview summary, or read the transcript below: View Audio Transcript GLP-1 agonists like Ozempic and Wegovy started as diabetes medications. But we're discovering they do far more than control blood sugar. These medications mimic a natural hormone that regulates glucose, appetite, and digestion. What makes them remarkable isn't just…